Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic to Test Stalled Pfizer Drug Candidates for New Indications

NEW YORK, Sept. 27 (GenomeWeb News) - Gene Logic will help Pfizer find new therapeutic indications for a number of its stalled drug candidates, Gene Logic said today.

 

Under the "drug repositioning program," Gene Logic will test drug candidates from Pfizer that are no longer in development for their potential use across a wide spectrum of diseases areas, using its genomics and in silico technologies as well as technologies it acquired from Millennium Pharmaceuticals last year. Gene Logic is eligible for milestone payments and royalties on drugs that are commercialized as a result of the program.

 

The companies did not disclose other terms of the agreement.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.